Systemic Mastocytosis (SM) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Systemic Mastocytosis (SM) is a rare hematological neoplasm characterized by heterogeneous clinical manifestations due to the excessive proliferation of abnormal clonal mast cells (MCs) in different cutaneous and extracutaneous sites, such as bone marrow (BM), spleen, lymph nodes, and the gastrointestinal (GI) tract. Somatic mutations in the KIT gene cause most cases of systemic mastocytosis. This gene encodes a protein that helps control critical cellular processes such as cell growth and division, survival, and movement. Mutations in the KIT gene lead to an overproduction of mast cells, which accumulate in internal organs and lead to the symptoms of this condition. The long-term outlook (prognosis) for people with systemic mastocytosis (SM) varies. Young children and those who present with primarily cutaneous and flushing symptoms tend to have little or no progression of the disease over a considerable length of time. Older patients and those with extensive, systemic diseases involving other organ systems have poorer prognoses. Systemic mastocytosis is further classified into; indolent SM (ISM), aggressive SM (ASM), Smoldering systemic mastocytosis (SSM), Systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and Mast cell leukemia (MCL).

 

The estimated incidence rate of Systemic Mastocytosis (SM) varies between 1 to 1.5 cases per 100,000 population in the USA.

 

The competitive landscape of Systemic Mastocytosis (SM) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Systemic Mastocytosis (SM) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Systemic Mastocytosis (SM) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Systemic Mastocytosis (SM) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          BLU-263           Blueprint Medicines Corporation Phase 2/3

2          Masitinib           AB Science       Phase 3

3          PA101  Patara Pharma  Phase 2

4          AK002  Allakos, Inc.      Phase 1

5          CGT9486 tablets           Cogent Biosciences, Inc.           Phase 2

6          Brentuximab vedotin      Seagen Inc.      Phase 2

7          Nilotinib Novartis Pharmaceuticals          Phase 1/2

8          GTB-3550         GT Biopharma, Inc.       Phase 1/2

9          DCC-2618         Deciphera Pharmaceuticals LLC Phase 1

 

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more